Hinge Bio
PrivateLast Round
Series A
Jan 15, 2025
Total Funding Raised
$30M
Momentum Score
25 /100
Company Overview
Hinge Bio, Inc. is a privately-held biotechnology company that develops therapeutics to address diseases such as autoimmunity, inflammatory disease, and cancer. The company utilizes its proprietary GEM-DIMER™ platform, which allows for the creation of multifunctional antibodies by merging multiple, fully-active antibodies into a single molecule. This technology is designed to enhance targeting and immune effector functions, creating treatments with superior safety and efficacy. Hinge Bio's lead program, HB2198, is being developed for the treatment of B cell-mediated autoimmune disorders like Systemic Lupus Erythematosus (SLE), with the goal of resetting the immune system through rapid and deep B cell depletion. The company announced a $30.6 million Series A financing in January 2025 to advance its lead candidate into clinical trials.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hinge Bio Comps
Public and private peers based on sector, stage, and business model.
Hinge Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 15, 2025 |
Key People
Founding team and executive leadership
Hinge Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Thornapple River Capital | Series A |
| Ridgeback Capital | Series A |
| InVivium Capital | Series A |
| Point72 | Series A |
| Lightswitch Capital | Series A |
| Point72 Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 13, 2025
Regulatory milestone achieved for Lupus therapy, enabling clinical trials.
- Oct 1, 2025
Partnered with Kyorin Pharmaceutical Co., Ltd. for multispecific antibody medicines.
Hinge Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Hinge Bio's valuation, stock price, and market status.
